This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. RSLS, CANF, RDHL, MBIO, SXTP, TCRT, SBFM, CDT, GLTO, and SILOShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include ReShape Lifesciences (RSLS), Can-Fite BioPharma (CANF), RedHill Biopharma (RDHL), Mustang Bio (MBIO), 60 Degrees Pharmaceuticals (SXTP), Alaunos Therapeutics (TCRT), Sunshine Biopharma (SBFM), Conduit Pharmaceuticals (CDT), Galecto (GLTO), and Silo Pharma (SILO). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. ReShape Lifesciences Can-Fite BioPharma RedHill Biopharma Mustang Bio 60 Degrees Pharmaceuticals Alaunos Therapeutics Sunshine Biopharma Conduit Pharmaceuticals Galecto Silo Pharma ReShape Lifesciences (NASDAQ:RSLS) and Conatus Pharmaceuticals (NASDAQ:CNAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Is RSLS or CNAT more profitable? Conatus Pharmaceuticals has a net margin of -52.42% compared to ReShape Lifesciences' net margin of -86.36%. Conatus Pharmaceuticals' return on equity of -48.22% beat ReShape Lifesciences' return on equity.Company Net Margins Return on Equity Return on Assets ReShape Lifesciences-86.36% -179.83% -91.48% Conatus Pharmaceuticals -52.42%-48.22%-39.32% Do analysts rate RSLS or CNAT? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ReShape Lifesciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Conatus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, RSLS or CNAT? ReShape Lifesciences has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Conatus Pharmaceuticals has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Does the media refer more to RSLS or CNAT? In the previous week, ReShape Lifesciences had 5 more articles in the media than Conatus Pharmaceuticals. MarketBeat recorded 5 mentions for ReShape Lifesciences and 0 mentions for Conatus Pharmaceuticals. ReShape Lifesciences' average media sentiment score of 0.32 beat Conatus Pharmaceuticals' score of 0.00 indicating that ReShape Lifesciences is being referred to more favorably in the media. Company Overall Sentiment ReShape Lifesciences Neutral Conatus Pharmaceuticals Neutral Do institutionals & insiders have more ownership in RSLS or CNAT? 22.1% of ReShape Lifesciences shares are held by institutional investors. Comparatively, 15.2% of Conatus Pharmaceuticals shares are held by institutional investors. 0.0% of ReShape Lifesciences shares are held by insiders. Comparatively, 11.3% of Conatus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor RSLS or CNAT? Conatus Pharmaceuticals received 139 more outperform votes than ReShape Lifesciences when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 66.11% of users gave ReShape Lifesciences an outperform vote. CompanyUnderperformOutperformReShape LifesciencesOutperform Votes39866.11% Underperform Votes20433.89% Conatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Which has stronger earnings & valuation, RSLS or CNAT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReShape Lifesciences$8.01M0.48-$11.39M-$13.72-0.02Conatus Pharmaceuticals$21.72M0.05-$11.39MN/AN/A SummaryConatus Pharmaceuticals beats ReShape Lifesciences on 8 of the 14 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.06M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.117.4422.5118.48Price / Sales0.05242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book0.066.516.774.25Net Income-$11.39M$143.21M$3.22B$248.23M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.03+7.0%N/A-91.5%$1.06M$21.72M-0.1130Gap UpRSLSReShape Lifesciences0.4275 of 5 stars$0.34-4.9%N/A-96.5%$3.91M$8.01M-0.0350Short Interest ↑Gap DownCANFCan-Fite BioPharma1.6655 of 5 stars$1.09-4.9%$14.00+1,179.7%-47.3%$3.86M$674,000.00-0.618Gap UpRDHLRedHill Biopharma1.0685 of 5 stars$2.18+0.5%N/A-99.2%$3.86M$8.04M0.00210Analyst ForecastGap DownMBIOMustang Bio2.6019 of 5 stars$1.17+0.8%$100.00+8,454.3%-91.2%$3.86MN/A-0.01100Positive NewsSXTP60 Degrees Pharmaceuticals0.4764 of 5 stars$2.61-6.5%N/A+133.2%$3.85M$607,574.00-0.263Gap DownTCRTAlaunos Therapeutics0.436 of 5 stars$2.40-2.2%N/A-80.6%$3.83M$10,000.000.0040Short Interest ↑Gap DownSBFMSunshine Biopharma3.2076 of 5 stars$1.40-3.1%$15.00+974.5%+54.3%$3.82M$34.87M-0.013Negative NewsGap UpCDTConduit Pharmaceuticals0.342 of 5 stars$0.56+3.1%N/A-99.8%$3.75MN/A-0.013Short Interest ↑Gap DownGLTOGalecto3.1118 of 5 stars$2.80+4.5%$10.00+257.1%-83.7%$3.70MN/A-0.1540Upcoming EarningsPositive NewsSILOSilo Pharma0.7445 of 5 stars$0.81-3.6%N/A-59.2%$3.64M$72,102.00-0.672News CoverageGap Down Related Companies and Tools Related Companies ReShape Lifesciences Competitors Can-Fite BioPharma Competitors RedHill Biopharma Competitors Mustang Bio Competitors 60 Degrees Pharmaceuticals Competitors Alaunos Therapeutics Competitors Sunshine Biopharma Competitors Conduit Pharmaceuticals Competitors Galecto Competitors Silo Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
